Join
Live feed
·
INSIDERFilingvia Quantisnow
Ionis Pharmaceuticals Inc. logo

EVP, Chief Scientific Officer Bennett C Frank sold $1,744,623 worth of shares (20,536 units at $84.95) as part of a pre-agreed trading plan and acquired 15,000 shares as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 75,018 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IONS (Ionis Pharmaceuticals Inc.) and more on Quantisnow.